Lupin US Subsidiary Settles Antitrust Case With Humana for $30 Million
Lupin’s wholly owned US unit, Lupin Pharmaceuticals Inc., reached a $30 million antitrust settlement with Humana Inc. tied to In Re Generic Pharmaceuticals Antitrust Litigation consolidated in Philadelphia, Pennsylvania. LPI denies the allegations, and Lupin says the settlement was already provided for in prior consolidated financial results. Lupin also announced the US commercial launch of dapagliflozin tablets for diabetes.